Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
As per available reports about 10 relevant journals, 13 Conferences, 92 workshops are presently dedicated exclusively to Organ transplantationand about 395 articles are being published on Organ transplantation.
Organ transplantation is the moving of an organ from a donor site to one more location on the patient's individual body, for the reason of restoring the recipient's damaged or deficient organ. The up-and-coming field of regenerative medication is permit scientists and engineers to generate organs to be re-grown from the patient's own cells. Organs that are relocated within the same person's body are identified as autografts. Transplants that are recently performed between two subjects of the identical species are called allografts. Allografts can either be from a existing or cadaveric source.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance:
Limited accessibility to transplantation is a major consequence of the ever shrinking organ donor rate. Improvement in accessibility to transplantation requires increasing the organ donor rates. However, that may not be entirely true. Experiences carried out in the USA have shown that social and racial minorities may not entirely benefit from organ resources and that even for transplantation they may bear the consequences of non-justifiable discrimination. But also within the EU there are huge differences in access that cannot merely be explained by differences in donation rates. Accessibility means to work hard on organ shortage, but also set up transparent healthcare processes, expand these processes to all social classes and racial categories, and constant monitoring of organ allocation modalities. Again, these goals are to be achieved only through active integration of all the actors involved in the transplant process: healthcare professionals, stakeholders and authorities. However, advances in reducing the regional variability of access to transplantation requires not only coordination among member states, but also creation of tools to balance the regional inequalities to transplant access within single nations. So far central authorities have not succeeded in overcoming access inequalities, and we strongly feel that any initiative to this regard should count on collaboration between Regions, if we want to succeed.
Transplantation medicine is one of the most challenging and complex areas of modern medicine. Some of the key areas for medical management are the problems of transplant rejection, during which the body has an immune response to the transplanted organ, possibly leading to transplant failure and the need to immediately remove the organ from the recipient. When possible, transplant rejection can be reduced through serotyping to determine the most appropriate donor-recipient match and through the use of immunosuppressant drugs.
Types of transplant:
Transplantation in obese individuals organ donors may be living or may have died of brain death or circulatory death. Most deceased donors are those who have been pronounced brain dead. Brain dead means the cessation of brain function, typically after receiving an injury (either traumatic or pathological) to the brain, or otherwise cutting off blood circulation to the brain breathing is maintained via artificial sources, which, in turn, maintains heartbeat. Once brain death has been declared the person can be considered for organ donation. Criteria for brain death vary. Because less than 3% of all deaths in the U.S. are the result of brain death, the overwhelming majority of deaths are ineligible for organ donation, resulting in severe shortages.
The global market for organ and tissue transplantation products and devices reached $56.9 billion in 2014. This market is estimated to grow at a compound annual growth rate (CAGR) of 7.1% to reach $64.4 billion by 2015 and nearly $90.6 billion by 2020. This report offers forecasts, by product segment, from 2015 through 2020, including supporting analyses for projections. Product segments covered consist of the solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valve) markets, along with the pharmaceuticals that accompany each market.
Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells and altered cancer cells.
International symposium and workshops
Relevant Society and Associations
This page will be updated regularly.
This page was last updated on January 18, 2020